Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AQL-Naltrexone
- Development stage
- Preclinical
- Lead developer
- Plumb Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
AQL-Naltrexone (AQL-Nal) is an extended-release, liposome-based formulation of naltrexone developed by Plumb Pharmaceuticals for the treatment of Opioid Use Disorder (OUD). The drug is designed as a subcutaneous injection that utilizes Plumb's proprietary AQL technology to provide sustained release of the active ingredient over multiple months. As a non-selective opioid receptor antagonist, naltrexone blocks the euphoric effects of exogenous opioids and reduces cravings, thereby assisting in the prevention of relapse in patients with opioid dependence. This formulation aims to improve patient compliance by reducing the frequency of administration compared to existing daily oral or monthly injectable naltrexone products.
- Other names
- AQL-Naltrexone
02
Targets
SIGMAR1 (Sigma non-opioid intracellular receptor 1)MOR (Mu opioid receptor)KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)
Beyond the preview
Go deeper on AQL-Naltrexone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AQL-Naltrexone.